a. Nuclear Countermeasure Activity of TP508 Linked to Restoration of Endothelial Function and Acceleration of DNA Repair. Olszewska-Pazdrak B, McVicar SD, Rayavara K, Moya SM, Kantara C, Gammarano C, Olszewska P, Fuller GM, Sower LE, Carney DH. Radiat Res. 2016 Aug;186(2):162-74. doi: 10.1667/RR14409.1. Epub 2016 Jul 7.PMID: 27388041 https://pubmed.ncbi.nlm.nih.gov/27388041/
b. Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity. Kantara C, Moya SM, Houchen CW, Umar S, Ullrich RL, Singh P, Carney DH. Lab Invest. 2015 Nov;95(11):1222-33. doi: 10.1038/labinvest.2015.103. Epub 2015 Aug 17.PMID: 26280221 https://pubmed.ncbi.nlm.nih.gov/26280221/
c. Radiomitigation and Tissue Repair Activity of Systemically Administered Therapeutic Peptide TP508 Is Enhanced by PEGylation. McVicar SD, Rayavara K, Carney DH. AAPS J. 2017 May;19(3):743-753. doi: 10.1208/s12248-016-0043-7. Epub 2017 Jan 17.PMID: 28097629 https://pubmed.ncbi.nlm.nih.gov/28097629/
The TP508 Solution for Nuclear Radiation Exposure
Mitigation of Radiation-Induced Vascular Damage
About Us
Chrysalis BioTherapeutics, Inc. is committed to helping improve people’s lives through innovation.
Let’s Socialize
Popular Post
Galveston firm to test potential ‘game-changer’ in lung disease treatment
September 29, 2023
Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug
Galveston firm to test potential ‘game-changer’ in lung disease treatment
GALVESTON An island biopharmaceutical company has received U.S. Food and Drug Administration clearance
Clinical Trials – Tissue Repair
a. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled